METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES

Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

Compositions and methods comprising hydrocarbon-stapled polypeptides

Mosaic HIV envelope immunogenic polypeptides

Immunoconjugates with an intracellularly-cleavable linkage

HIV-1 vaccine

Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator

Anti-HIV domain antibodies and method of making and using same

CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS

Humanized or chimeric CD3 antibodies

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domain

Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications

CROSSLINKED ANTI-HIV-1 COMPOSITIONS FOR POTENT AND BROAD NEUTRALIZATION

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

Immunoconjugates with an intracellularly-cleavable linkage

STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS

Compositions for preventing and/or treating an infection by an HIV-1 virus

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

Neutralizing antibodies to HIV-1 and their use

THERAPEUTIC AGENT

HIV Antigens and Antibodies

Methods for producing antibodies

Broadly neutralizing antibody and uses thereof

Inert format

System and method for detecting pathogens

Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb

Compositions and methods for generating a synthetic antibody

SYNTHETIC ENV PROTEINS

Broadly-neutralizing anti-HIV antibodies

Recombinant bi-functional fusion proteins, preparations and methods for treating disease

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Antibodies with simultaneous subsite specificities to protein and lipid epitopes

ADCC-MEDIATING ANTIBODIES, COMBINATIONS AND USES THEREOF

Methods for identifying HIV neutralizing antibodies

ENHANCED RAPID IMMUNOGEN SELECTION METHOD FOR HIV GP120 VARIANTS

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers

Immunoconjugates with an intracellularly-cleavable linkage

Dimeric protein with triple mutations

Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain

IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME

Immunoconjugates with an intracellularly-cleavable linkage

Immunoconjugates with an intracellularly-cleavable linkage

BROADLY NEUTRALIZING VHH AGAINST HIV-1

Bispecific HIV-1 neutralizing antibodies

Immunogenic compounds comprising HIV GP41 peptide coupled to CRM197 carrier protein

Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine

Highly immunogenic peptides derived from the human immunodeficiency virus V2 region

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

Antibody composition-producing cell

NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE

Immunoglobulins with reduced aggregation

Neutralizing GP41 antibodies and their use

Neutralizing GP41 antibodies and their use

GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus

Immunogens comprising human immunodeficiency virus V1/V2 polypeptides

POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

Immunoconjugates with an intracellularly-cleavable linkage

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

HIV-1 gp120 mini V3 loop and uses thereof

Immunoconjugates with an intracellularly-cleavable linkage

DETECTION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN CANCER AND NORMAL CELLS

Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

Method of inducing the production of protective anti-HIV-1 antibodies

Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing

Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments

Camptothecin-binding moiety conjugates

Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction

Immunoconjugates with an intracellularly-cleavable linkage

Drug target site within gp120 of HIV

Rapid selection method for HIV gp-120 variants

Compositions for detecting an infection by an HIV-1 virus

HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies

Engineered antibody constant domain molecules

Antibodies targeting HIV escape mutants

Binding molecules

Binding molecules

Constructs and methods to identify antibodies that target glycans

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

HIV-1 broadly neutralizing antibodies

Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth

BIVALENT MOLECULES FOR HIV ENTRY INHIBITION

High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins

Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein

ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE

METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY

METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION

Heterodimeric antibody Fc-containing proteins and methods for production thereof

Broadly cross-reactive HIV-1 Env-specific antibodies

Camptothecin-binding moiety conjugates

METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

Neutralizing antibodies to HIV-1 and their use

ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE

Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics

HIV-1 ANTIBODIES

DONOR SPECIFIC ANTIBODY LIBRARIES

Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain

METHOD OF DELIVERING RNA INTERFERENCE AND USES THEREOF

ANTIGEN-ANTIBODY COMPLEXES AS HIV-1 VACCINES

NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE

Neutralizing antibodies to HIV-1 and their use

VIRAL POLYPEPTIDES AND METHODS

Detection of HIV-related proteins in urine

Detection of HIV-related proteins in urine

Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity

Method of inducing neutralizing antibodies to human immunodeficiency virus

MIMOTOPES OF HIV ENV

ALPHABODIES FOR HIV ENTRY INHIBITION

MIMOTOPES OF HIV AND USES THEREOF

Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region

HIV CD4 BINDING SITE BASED COVALENT IMMUNOGEN COMPOSITIONS

Fusion antibodies for HIV therapy

Therapeutic Agent

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

Immunoconjugates with an intracellularly-cleavable linkage

Peptidic antigen that induces antibody recognizing three-dimensional structure of HIV and method for synthesizing same

AGENT FOR SUPPRESSING REPLICATION OF HIV AND USE THEREOF

ANTIBODY GENE TRANSFER AND RECOMBINANT AAV THEREFOR

Immunoglobulins with reduced aggregation

Compositions and methods for the treatment of viral infections

HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof

Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases

Immunoconjugates with an intracellularly-cleavable linkage

Bifunctional Griffithsin Analogs

VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHODS OF DIAGNOSIS

Antibody composition-producing cell

Motif-grafted hybrid polypeptides and uses thereof

MONOCLONAL ANTIBODY PRODUCTION IN B CELLS AND USES THEROF

Method of detecting antibodies and antibody-hiv virion complexes

Rapid expression cloning of human monoclonal antibodies from memory B cells

HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF

Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine

CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE

Glycan markers and autoantibody signatures in HIV-1 and HIV-1-associated malignancies

METHODS FOR PRODUCING ANTIBODIES

METHODS OF TREATING AND PROTECTING AGAINST HUMAN IMMUNODEFICIENCY VIRUS

Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41

UNIVERSAL LIBRARIES FOR IMMUNOGLOBULIN

Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom

BINDING MOLECULES

VECTORS FOR DELIVERING DISEASE NEUTRALIZING AGENTS

Anti-HIV domain antibodies and method of making and using same

Soluble stabilized trimeric hiv env proteins and uses thereof

Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody

VACCINE

Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation

Antibodies

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Cellular and viral inactivation

REAGENTS FOR INDUCING AN IMMUNE RESPONSE

ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

IDENTIFICATION OF NOVEL BROADLY CROSS-REACTIVE NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES USING SEQUENTIAL ANTIGEN PANNING OF PHAGE DISPLAY LIBRARIES

HIV-1 envelope glycoprotein oligomer and methods of use

Engineered antibody constant domain molecules

Therapeutic Agent

DONOR SPECIFIC ANTIBODY LIBRARIES

Immunoconjugates for treatment of infectious diseases

RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

Binding molecules

Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction

Anti-PD-L1 antibodies, compositions and articles of manufacture

Binding molecules

Therapeutic peptides and vaccines

Mannose immunogens for HIV-1

Immunoglobulins directed to bacterial, viral and endogenous polypeptides

VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHOD OF DIAGNOSIS

Methods for increasing the diversity of monoclonal antibodies produced against an antigen

Methods for modulating the efficacy of nucleic acid based therapies

Antibody Composition-Producing Cell

Immunoconjugates with an intracellularly-cleavable linkage

Altered Immunogenic Landscape in HIV-1 Envelope Proteins

Detection of HIV-related proteins in urine

Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules

Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates

Vector System

Method for engineering immunoglobulins

Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus

Camptothecin-binding moiety conjugates

Tetramers

Catalytic Immunoglobulins BBK32 and Uses Therefor

Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency

Binding molecules

exotoxin A-like chimeric immunogens

Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2

Cells with altered fucosylation and producing antibodies therefrom

Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid

Use of HIV envelope/CD4 complexes for the generation antibodies

Antibody-drug conjugates and methods

Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation

Antibody or a fragment thereof, having neutralizing activity against HIV

Glycoengineered, recombinant antibody

POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL

Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env

Binary epitope antibodies and B cell superantigen immune stimulants

Purified antibody to the extracellular domain of NKp44L

PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE

Virus coat protein/receptor chimeras and methods of use

Antibody Gene Transfer and Recombinant AAV Therefor

Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs

IMMUNE COMPLEX VACCINATION AS A STRATEGY TO ENHANCE IMMUNITY IN THE ELDERLY AND OTHER IMMUNE COMPROMISED POPULATIONS

Immunoglobin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same

Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

Preparation of fully human antibodies

Administration of transposon-based vectors to reproductive organs

Gene regulation in transgenic animals using a transposon-based vector

Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase

Immunogen

Env polypeptide complexes and methods of use

Antibody-drug conjugates and methods

Methods for Modulating the Efficacy of Nucleic Acid Based Therapies

Camptothecin-binding moiety conjugates

Method of delivering RNA interference and uses thereof

Universal Libraries for Immunoglobulins

Donor specific antibody libraries

Identification of the Precise Amino Acid Sequence of the Epitope Recognized by the Potent Neutralizing Human Anti-Hiv-1 Monoclonal Antibody Igg1b12

Molecular scaffolds for HIV-1 epitopes

Method of inducing neutralizing antibodies to human immunodeficiency virus

Anti-HIV antibody

Glycosylated polypeptides produced in yeast mutants and methods of use thereof

A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

Polynucleotides encoding modified HIV-1 gp41 membrane polypeptides

Immunogenic proteoliposomes, and uses thereof

Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies

Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Antibodies

Human antibodies interacting with HIV gp41

Immunoglobulins with Potent and Broad Antiviral Activity

Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes

Immunoconjugates with improved efficacy for the treatment of diseases

Covalent attachment of ligands to nucleophilic proteins guided by non-covalent

Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence

Immunogenic compositions comprising human immunodeficiency virus type 2 (HIV-2) glycosylated and unglycosylated envelope proteins and their methods of preparation

Combination approaches for generating immune responses

Quantifying and profiling antibody and t cell receptor gene expression

Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes

Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same

Lupus antibodies for passive immunotherapy of HIV/AIDS

Proteolytic and covalent antibodies

Compositions and liquid crystals

Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual

Assay

Antibodies with simultaneous subsite specificities to protein and lipid epitopes

Specificity exchangers that redirect antibodies to a pathogen

Antibody Composition-Producing Cell

Therapeutic peptides and vaccines

Method for enhancing efficacy of preparation of monoclonal antibody

Peptide oligomers for use as hiv vaccines

Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual

Mannose immunogens for HIV-1

Immunogen

Camptothecin-binding moiety conjugates

Method of promoting an immune response with a bispecific antibody

Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

Pharmaceutical compositions comprising an hiv envelope protein and cd4

Methods for increasing the diversity of monoclonal antibodies produced against an antigen

Specificity exchangers that redirect antibodies to a pathogen

Immunogens for hiv vaccine

Immunotherapy regimens in hiv-infected patients

Anti-HIV composition, production method thereof and medicament

Antibody composition-producing cell

Mammalian host cell modified by RNAi to inhibit α 1,6-fucosyltransferase

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis

Antibody composition-producing cell

Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation

Antibodies

Antibody-drug conjugates and methods

Antibody composition-producing cell

Virus coat protein/receptor chimeras and method of use

Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease

Combined chemotherapy compositions and methods for the treatment of cancer, ischemia-reperfusion injury, and septic shock

Peptides that bind to broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex. uses thereof, compositions therefrom

Diagnostic device using GP40

Therapeutic supramolecules

Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency

Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same

Covalently reactive transition state analogs and methods of use thereof

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Detection of HIV-1 DNA

Pseudomonas exotoxin A-like chimeric immunogens for eliciting a secretory IgA-mediated immune response

Use of transgenic mice for the efficient isolation of novel human monoclonal antibodies with neutralizing activity against primary HIV-1 strains and novel HIV-1 neutralizing antibodies

Polynucleotide encoding a mutated HIV gp41 polypeptide

Preparation of fully human antibodies

Domain-exchanged binding molecules, methods of use and methods of production

Methods for identifying aptamer regulators